These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 1400073)

  • 1. Treatment of von Willebrand's disease.
    Logan LJ
    Hematol Oncol Clin North Am; 1992 Oct; 6(5):1079-94. PubMed ID: 1400073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of von Willebrand's Disease.
    Mannucci PM
    N Engl J Med; 2004 Aug; 351(7):683-94. PubMed ID: 15306670
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of von Willebrand's disease.
    Mannucci PM
    J Intern Med Suppl; 1997; 740():129-32. PubMed ID: 9350194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Von Willebrand's disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment.
    Castaman G; Federici AB; Rodeghiero F; Mannucci PM
    Haematologica; 2003 Jan; 88(1):94-108. PubMed ID: 12551832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings.
    Michiels JJ; van Vliet HH; Berneman Z; Schroyens W; Gadisseur A
    Acta Haematol; 2009; 121(2-3):167-76. PubMed ID: 19506363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of inherited von Willebrand disease in 2007.
    Federici AB; Mannucci PM
    Ann Med; 2007; 39(5):346-58. PubMed ID: 17701477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Desmopressin in hemophilia A and Von Willebrand's disease].
    Castro Cabezas M; de Graaf JC; Kraayenhagen RJ; Freen M; Poortman J; Hart HC
    Ned Tijdschr Geneeskd; 1991 Mar; 135(9):367-71. PubMed ID: 1901629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. von Willebrand disease: from the bedside to therapy.
    Aledort LM
    Thromb Haemost; 1997 Jul; 78(1):562-5. PubMed ID: 9198216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of factor VIII/von Willebrand's factor concentrate (Haemate-P) in preventing bleeding during surgery or invasive procedures in patients with von Willebrand disease.
    Franchini M; Rossetti G; Tagliaferri A; Pattacini C; Pozzoli D; Lippi G; Manzato F; Bertuzzo D; Gandini G
    Haematologica; 2003 Nov; 88(11):1279-83. PubMed ID: 14607757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Perioperative therapy of von Willebrand disease. Demonstration of pathophysiology, clinical problems and therapy options using two case reports].
    Kleinschmidt S; Fuchs-Buder T; Wilhelm W; Seyfert UT; Mörsdorf S
    Anaesthesist; 2002 Oct; 51(10):825-34. PubMed ID: 12395174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PFA-100 monitoring of von Willebrand factor (VWF) responses to desmopressin (DDAVP) and factor VIII/VWF concentrate substitution in von Willebrand disease type 1 and 2.
    van Vliet HH; Kappers-Klunne MC; Leebeek FW; Michiels JJ
    Thromb Haemost; 2008 Sep; 100(3):462-8. PubMed ID: 18766263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [An inherited hemostatic disorder as the cause of menorrhagia].
    Leebeek FW; Lotgering FK
    Ned Tijdschr Geneeskd; 2002 Mar; 146(12):545-8. PubMed ID: 11938574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. von Willebrand disease and pregnancy: a practical approach for the diagnosis and treatment.
    Pacheco LD; Costantine MM; Saade GR; Mucowski S; Hankins GD; Sciscione AC
    Am J Obstet Gynecol; 2010 Sep; 203(3):194-200. PubMed ID: 20417473
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Von Willebrand's disease: clinical management.
    Federici AB; Castaman G; Thompson A; Berntorp E
    Haemophilia; 2006 Jul; 12 Suppl 3():152-8. PubMed ID: 16684011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3.
    Michiels JJ; Gadisseur A; van der Planken M; Schroyens W; van de Velden A; Berneman Z
    Semin Thromb Hemost; 2006 Sep; 32(6):636-45. PubMed ID: 16977574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Von Willebrand's disease].
    Furlan M
    Schweiz Med Wochenschr; 1987 Nov; 117(46):1798-806. PubMed ID: 3122318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of von Willebrand's disease.
    Logan LJ
    Prog Clin Biol Res; 1990; 324():279-90. PubMed ID: 2106690
    [No Abstract]   [Full Text] [Related]  

  • 19. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
    Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Hemostatic effect of deamino-8-D-arginine vasopressin (DDAVP) in hemophilia A and von Willebrand's disease].
    Fukui H; Takase T
    Rinsho Ketsueki; 1985 Jul; 26(7):1069-79. PubMed ID: 3932720
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.